Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL5492529 | 1.00 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL10456349 | 0.98 | SLC22A6 (0.36) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL14343482 | 0.97 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL249319 | 0.97 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL11696724 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL4823149 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL11586415 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL10597783 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL11111882 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL896679 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587119-A1 | METHODS OF TREATMENT WITH AN IBOGA ALKALOID | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-07-23 | — | — | EP | claimed |
| US-20240415872-A1 | OPHTHALMIC FORMULATIONS FOR TREATMENT OF PRESBYOPIA, DRY EYE DISEASE AND COMPUTER VISION SYNDROME | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2024-12-19 | — | — | US | claimed |
| US-20240408118-A1 | AN OPHTHALMIC FORMULATION FOR TREATMENT AND PREVENTION OF CATARACT AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2024-12-12 | — | — | US | claimed |
| EP-4419145-A1 | OPHTHALMIC FORMULATIONS FOR TREATMENT OF PRESBYOPIA, DRY EYE DISEASE AND COMPUTER VISION SYNDROME | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2024-08-28 | — | — | EP | claimed |
| EP-4419204-A1 | AN OPHTHALMIC FORMULATION FOR TREATMENT AND PREVENTION OF CATARACT AND PRODUCTION METHOD THEREOF | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2024-08-28 | — | — | EP | claimed |
| US-20240100062-A1 | Methods of Treatment With an Iboga Alkaloid | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-28 | — | — | US | claimed |
| US-20240100061-A1 | Compositions of Iboga Alkaloids and Methods of Treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-28 | — | — | US | claimed |
| WO-2024059717-A1 | METHODS OF TREATMENT WITH AN IBOGA ALKALOID | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-21 | — | — | WO | claimed |
| EP-4326284-A1 | INJECTABLE HYALURONIC ACID FORMULATIONS FOR USE IN INTRAARTICULAR, INTRADERMAL AND OPHTHALMIC APPLICATIONS | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2024-02-28 | — | — | EP | claimed |
| WO-2023069036-A1 | AN OPHTHALMIC FORMULATION FOR TREATMENT AND PREVENTION OF CATARACT AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-04-27 | — | — | WO | claimed |
| EP-1854453-A1 | Aqueous composition with shelf life stability comprising a magnesium compound and L-carnitine | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 2007-11-14 | — | — | EP | claimed |
| US-20070196469-A1 | Magnesium microtablets with sustained release | VERLA-PHARM ARZNEIMITTELFABRIK APOTHEKER H.J.V. EHRLICH GMBH & CO. (DE) | 2007-08-23 | — | — | US | claimed |
| EP-1762231-A1 | Sustained release magnesium microtablets | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 2007-03-14 | — | — | EP | claimed |
| US-20070043229-A1 | Process for preparing certain hydrohalide metal complex compounds having a specific coarse structure | VERLA-PHARM ARZNEIMITTELFABRIK APOTHEKER J.J.V. EHRLICH GMBH & CO. KG (DE) | 2007-02-22 | — | — | US | claimed |
| EP-1627879-B1 | Process for preparing hydrohalogen metal complexes of specific particle size | VERLA PHARM (DE) | 2006-10-18 | — | — | EP | claimed |
| CN-1836655-A | Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses | SHENYANG YAOLIAN TECHNOLOGICAL (CN) | 2006-09-27 | — | — | CN | claimed |
| EP-1627879-A1 | Process for preparing hydrohalogen metal complexes of specific particle size | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 2006-02-22 | — | — | EP | claimed |
| EP-0340540-B1 | AGENT FOR THE PROPHYLAXIS OF A HEART INFARCT AND FOR THE PREVENTION OF ANOTHER INFARCT | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 1991-10-30 | — | — | EP | claimed |
| EP-0074426-B1 | PHARMACEUTICAL ORAL DOSAGE FORMS OF AN ACTIVE AGENT CAPABLE OF FORMING OR RELEASING BICARBONATE IONS | Olima Holding AG (CH) | 1985-11-21 | — | — | EP | claimed |
| EP-0108937-A2 | Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and novel such complexes | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 1984-05-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100061-A1 | Compositions of Iboga Alkaloids and Methods of Treatment | GAP43, PYGB, INA | SLC22A6 2340/4885GABRR1 303/4885LMNA 209/4885 |
| US-20070043229-A1 | Process for preparing certain hydrohalide metal complex compounds having a specific coarse structure | SLC7A5, HRH4, SLC7A1 | SLC22A6 687/4885GABRR1 3529/4885LMNA 4306/4885 |
| US-20240100062-A1 | Methods of Treatment With an Iboga Alkaloid | INA, GAP43, PYGB | SLC22A6 2904/4885GABRR1 331/4885LMNA 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.